英文药名: Potassium Citrate(K Citra Tablets)

中文药名: 柠檬酸钾片

药品简介

柠檬酸钾片是预防由于钙或尿酸高引起的肾尿结石的常用药物。柠檬酸钾通过恢复自然化学物质，从而阻止结石形成。使尿环境正常化，抑制钙晶体结石的形成。柠檬酸钾片也有降低形成结石的尿酸趋势。大部分的病人通过柠檬酸钾片治疗都没有形成结石。有些仍然结石的病人, 石头形成的比以前缓慢.

规格
10meq (1080mg)*100 片
   
5meq (540mg)*100 片

Urocit-K (potassium citrate) is an oral medication used to prevent calcium oxalate bladder stones by alkalinizing, or increasing the urine pH.

FORMULATION:
Each tablet contains:
Potassium Citrate .............................................................(10mEq) 1,080 mg

INDICATIONS:
- Treatment of patients with renal lithiasis and hypocitraturia, chronic
Formers of calcium oxalate, phosphate calculia
- Uric acid lithiasis alone or accompanied by calcium lithiasis
- Tubular acidosis with calcium nephrolithiasis

DOSAGE:
The aim of the treatment is to restore the level of the urinary citrate and to increase the pH of urine to 6-7, and to this end, the dosage pattern are:
- In patients with severe hypocitraturia start the treatment with a dose of 60mEq (6 tablets) daily, divided into 3 takings daily.
- In patients with mild hypocitraturia start the treatment with a dose of 30mEq (3 tablets) daily, divided into 3 takings daily.

It is recommended to take the tablets 30 minutes after meals. Approximately 24 hours after having started the treatment, make determination of urinary citrate and pH, and adjust the dose in accordance with the needs of the patient. If necessary, the dose can be increased, though it is not advisable to exceed the dose of 100 mEq (10 tablets) /day.

IMPORTANT NOTE:
THE TABLETS MUST NOT BE MASTICATED OR DILUTED.
The active component of Acalka (potassium citrate) is contained within a porous wax matrix. As this WAX MATRIX IS INSOLUBLE, IT CAN BE ELIMINATED IN VISIBLE FORM IN THE FECES. The active component, however, has been released in the gastrointestinal tract.

CONTRAINDICATION:
Renal Insufficiency
Persistent alkaline urinary infections
Obstruction of the Urinary tract
Hyperpotassemia
Adrenal insufficiency
Respiratory or metabolic alkalosis
Active peptic ulcer
Intestinal obstruction
Patients submitted to anticholinergic therapy
Patients with slow gastric emptying
INTERACTIONS:
Must not be administered to patients receiving potassium-sparing diuretics (triamtrene, spirolactone or amyloride)

ADVERSE REACTIONS:
Slight gastrointestinal disorders may appear which can be palliated by means of the joint administration of food.

PRECAUTIONS AND WARNINGS:
In patients with altered potassium excretion mechanism, hyperpotassemia may appear.

In patients with renal insufficiency there is an increased risk of appearance of hyperpotassemia, and, for this reason, it is advised not to exceed the recommended doses.

It is advisable to carry out an evaluation of electrolytes (Na-K-Cl) and CO2, createnine and hemogram every 4 hours.

It is recommended that during pregnancy and lactation, the product is administered upon strict medical control.

It is recommended that patients in treatment with ACALKA follow a diet without salt and increase intake of liquids.

Once the active principle is released, the porous wax matrix, in which it was contained for its gradual release, can be eliminated in a still visible way in the feces.

CAUTION:
Food, drugs, Devices and Cosmetics Act prohibits the dispensing without prescription.

OVERDOSAGE AND ITS TREATMENT:
The long-term administration in patients having a trend to retain potassium may produce hyperpotassemia. In advanced phase, muscular paralysis and cardiovascular collapse may be produced.

The recommended treatment in case of hyperpotassemia is: IV administration of 10% dextrose solution, containing 10-12 units of insulin/1000ml. Correction of the possible acidosis with IV sodium bicarbonate and hemodialysis or peritoneal dialysis.

AVAILABILITY: Bottles of 100's

STORE AT TEMPERATURE NOT EXCEEDING 30°C